🔎 Trials Near Me

Home › Soft Tissue Sarcoma

Soft Tissue Sarcoma clinical trials recruiting in the U.S.

135 studies for Soft Tissue Sarcoma are recruiting participants at sites across the United States.

Soft tissue sarcoma refers to cancer that begins in the muscle, fat, vessels or tendons. It can cause a lump or swelling. See which treatments are available

Cities with the most studies

By state

Recently updated studies

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

RecruitingObservational studyHealthy volunteers welcome
4 Weeks · All sexes · Updated Sep 28, 2026 · NCT01109394

DESTINY-PANTUMOUR04

RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07229313

Anti-GD2 ADC M3554 in Advanced Solid Tumors

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06641908

A Study of CRD3874-SI in People With Solid Tumors

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT06021626

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07705334

FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

RecruitingPhase 1
Ages 3 to 39 · All sexes · Updated Sep 14, 2026 · NCT06865664

Biomarkers of Resiliency In Childhood Cancer Surgery

RecruitingObservational study
Ages 3 to 25 · All sexes · Updated Sep 14, 2026 · NCT06674811

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06797999

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

RecruitingPhase 1
Ages 12 to 85 · All sexes · Updated Sep 8, 2026 · NCT03715933

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT04577014

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05732831

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06644755

Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

RecruitingPhase 1/2
Ages 12 to 40 · All sexes · Updated Sep 3, 2026 · NCT07725380

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

RecruitingPhase 1
Ages 5 to 40 · All sexes · Updated Sep 3, 2026 · NCT06156410

GRID Therapy for Extremity Soft Tissue Sarcoma

Recruiting
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06073067

Serial MRI Scans During Radiation Therapy

Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT04188535

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT05837767

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

RecruitingObservational study
Ages 18 to 50 · Women · Updated Sep 2, 2026 · NCT06904365

Actinium Therapy for Late-stage Aggressive Sarcomas

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07156565

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.